Improving Patient Education and Reducing Risk

Isotretinoin, marketed as Accutane® by Roche Pharmaceuticals, has become a support in the governance of severe recalcitrant acne.
It is increasingly state prescribed for milder acne cases as well.
An estimated 500,000 new patients are treated each year. While the efficacy of isotretinoin has been clearly demonstrated, the benefits of therapy must be weighed against the electric potential for significant adverse events.
In the last year, changes in the good labeling and new informed consent documents have been created in an attempt to gambler educate patients about the risks associated with isotretinoin use.
This is a part of article Improving Patient Education and Reducing Risk Taken from "Acne Isotretinoin Accutane" Information Blog